Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04651166 · ClinicalTrials.gov registry record · Phase 2
Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation
A Phase 2 study of Hemorrhage and Blood Loss, sponsored by University of Hawaii.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04651166 is a Phase 2 study of Hemorrhage and Blood Loss that has completed, run by University of Hawaii. The registered enrollment target is 48 participants, below the 264-participant average among 20 other Hemorrhage trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04651166, a Phase 2 study of Hemorrhage and Blood Loss, has completed, sponsored by University of Hawaii.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Prophylactic tranexamic acid has shown been shown to reduce maternal mortality from postpartum hemorrhage with no adverse effects, but has not been studied to reduce bleeding complications with dilation and evacuation (D\&E). We propose a randomized, double-blinded, placebo-controlled pilot study to determine whether routine use of intravenous (IV) tranexamic acid will decrease the need for interventions to control bleeding at the time of D\&E at 16 to 24 weeks gestation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tranexamic acid
Study Locations (1)
Hawaii
- Queens Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04651166
The ClinicalTrials.gov registry entry for NCT04651166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 20 other Hemorrhage trials with a reported enrollment target (82% lower). The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04651166 reports 1 study location spanning 1 distinct geographic area - top geographies include Hawaii.
Frequently Asked Questions
What is clinical trial NCT04651166 about?
NCT04651166 is a clinical study titled "Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation". Prophylactic tranexamic acid has shown been shown to reduce maternal mortality from postpartum hemorrhage with no adverse effects, but has not been studied to reduce bleeding complications with dilation and evacuation (D\&E). We propose a randomized, double-blinded, placebo-controlled pilot study to...
What is the current status of trial NCT04651166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2022-02-15. Estimated completion is 2023-07-27.
What conditions does trial NCT04651166 study?
This clinical trial studies the following conditions: Hemorrhage, Blood Loss, Abortion, Dilation and Evacuation.
What interventions are being tested in trial NCT04651166?
The interventions under investigation include: Placebo (DRUG), Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT04651166?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04651166 being conducted?
This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
RECRUITING · Phase 2
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
RECRUITING · Phase 4
-
The Effect of Fluids on Aortic VTI During C-section
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.